Evidence map›Paper›PMID 34486070›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2022

The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study).

Matteo Bauckneht, Sara Elena Rebuzzi, Alessio Signori, Viviana Frantellizzi, Veronica Murianni, Elisa Lodi Rizzini, Manlio Mascia, Valentina Lavelli, Maria Isabella Donegani, Marta Ponzano and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. [Development and validation of nomogram for predicting prognosis of patients with laryngeal squamous cell carcinoma after surgery].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2022
    Trial
  10. Observational
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Matteo Bauckneht *Nuclear Medicine, IRCCS Ospedale Policlinico San Martino, Genova, Italy. matteo.bauckneht@hsanmartino.it.ORCID http://orcid.org/0000-0002-1937-9116
Sara Elena Rebuzzi *Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Alessio SignoriDepartment of Health Sciences (DISSAL), University of Genova, Genova, Italy.
Viviana FrantellizziDepartment of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Rome, Italy.
Veronica MurianniMedical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Elisa Lodi RizziniRadiation Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
Manlio MasciaUnit of Nuclear Medicine, Spirito Santo Hospital, Pescara, Italy.
Valentina LavelliNuclear Medicine Section, Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy.
Maria Isabella DoneganiNuclear Medicine, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Marta PonzanoDepartment of Health Sciences (DISSAL), University of Genova, Genova, Italy.
Angela GaudianoNuclear Medicine Section, Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy.
Maria Lina StazzaUnit of Nuclear Medicine, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
Maria LicariUnit of Nuclear Medicine, Biomedical Department of Internal and Specialist Medicine, University of Palermo, Palermo, Italy.
Letizia CavalliniRadiation Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
Viola LaghiRadiation Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
Luca CindoloDepartment of Urology, Villa Stuart Private Hospital, Rome, Italy.
Martina MaggiDepartment of Urology, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy.
Alessandro SciarraDepartment of Urology, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy.
Paolo MammucciNuclear Medicine Section, Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy.
Gianmario SambucetiNuclear Medicine, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Renato Patrizio CostaUnit of Nuclear Medicine, Biomedical Department of Internal and Specialist Medicine, University of Palermo, Palermo, Italy.
Angela SpanuUnit of Nuclear Medicine, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
Giuseppe RubiniNuclear Medicine Section, Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy.
Fabio MonariRadiation Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
Giuseppe De VincentisDepartment of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Rome, Italy.
Giuseppe FornariniMedical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo combine peripheral blood indices and clinical factors in a prognostic score for metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 dichloride ([ PATIENTS AND

methodsBaseline neutrophil-to-lymphocyte ratio (NLR), derived NLR (donor), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), systemic inflammation index (SII), Eastern Cooperative Oncology Group performance status (ECOG PS), Gleason score (GS) group, number of bone metastases, prostate-specific antigen (PSA), alkaline phosphatase (ALP), line of therapy, previous chemotherapy, and the presence of lymphadenopathies were collected from seven Italian centers between 2013 and 2020. Lab and clinical data were assessed in correlation with the overall survival (OS). Inflammatory indices were then included separately in the multivariable analyses with the prognostic clinical factors. The model with the highest discriminative ability (c-index) was chosen to develop the BIO-Ra score.

resultsFive hundred and nineteen mCRPC patients (median OS: 19.9 months) were enrolled. Higher NLR, dNLR, PLR, and SII and lower LMR predicted worse OS (all with a p < 0.001). The multivariable model including NLR, ECOG PS, number of bone metastases, ALP, and PSA (c-index: 0.724) was chosen to develop the BIO-Ra score. Using the Schneeweiss scoring system, the BIO-Ra score identified three prognostic groups (36%, 27.3%, and 36.6% patients, respectively) with distinct median OS (31, 26.6, and 9.6 months, respectively; hazard ratio: 1.62, p = 0.008 for group 2 vs. 1 and 5.77, p < 0.001 for group 3 vs. 1).

conclusionsThe BIO-Ra score represents an easy and widely applicable tool for the prognostic stratification of mCRPC patients treated with [

Indexed as

Prostatic Neoplasms, Castration-ResistantRadiumHumansLymphocytesMalePrognosisRetrospective StudiesRadiumRadium-223[223Ra]RaCl2Clinical factorsInflammatory indicesMetastatic castration-resistant prostate cancerNeutrophil-to-lymphocyte ratio

Identifiers

PMID34486070
PMCPMC8803683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.